Differentially expressed tRFs in CD5 positive relapsed & refractory diffuse large B cell lymphoma and the
Qingyuan Qu1, Ying Li1, Xiaosheng Fang1
1Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong University, No.324, Jingwu Road, Jinan, Shandong, 250021, People's Republic of China.
Background:
Patients diagnosed as diffuse large B cell lymphoma (DLBCL) with CD5 positive normally have a worse outcome and poorly respond to the regulatory treatment strategy.
Results:
We recently reported differently expressed tRFs and their potential target-genes of tRFs in patients with CD5+ R/R DLBCL. Differently expressed tRFs were detected by Illumina NextSeq instrument and the results were verified by quantitative real-time reverse transcription-PCR. tRF2Cancer database was searched to compared with the results. Further research was performed through bio-informatic analysis including gene ontology (GO) and pathway enrichment analyses, etc. A total of 308 tRFs were identified. Two sequences (AS-tDR-008946, AS-tDR-013492) were chosen for further investigated.
Conclusions:
The results of Bioinformatics analysis revealed that the target genes including NEDD4L and UBA52 and several associated pathways including PI3K/AKT and MAPK/ERK might be involved in the development of CD5+ R/R DLBCL. Our preliminary study on the associated tRFs might provide a valuable measure to explore the pathogenesis and progression of CD5+ R/R DLBCL.
Reviewers:
This article was reviewed by Zhen Qing Ye, Nagarajan Raju and Jin Zhuang Dou.
Insights
CD5-positive diffuse large B cell lymphoma (DLBCL) patients often have poor outcomes. This study identified specific tRNA-derived fragments (tRFs) and their target genes, offering new insights into CD5+ R/R DLBCL pathogenesis.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- CD5-positive diffuse large B cell lymphoma (DLBCL) is associated with poor prognosis and resistance to standard treatments.
- Identifying novel biomarkers and therapeutic targets is crucial for improving outcomes in CD5+ R/R DLBCL.
Purpose of the Study:
- To investigate the role of tRNA-derived fragments (tRFs) in CD5-positive relapsed/refractory (R/R) DLBCL.
- To identify specific tRFs and their target genes involved in the pathogenesis of this aggressive lymphoma subtype.
Main Methods:
- Differentially expressed tRFs were identified using Illumina NextSeq.
- Quantitative real-time reverse transcription-PCR validated tRF expression.
- Bioinformatic analyses, including gene ontology and pathway enrichment, were performed.
Main Results:
- A total of 308 tRFs were identified in CD5+ R/R DLBCL patients.
- Two specific tRFs (AS-tDR-008946, AS-tDR-013492) were selected for further investigation.
- Target genes such as NEDD4L and UBA52, and pathways like PI3K/AKT and MAPK/ERK, were implicated.
Conclusions:
- The identified tRFs and their associated pathways may play a significant role in the development and progression of CD5+ R/R DLBCL.
- This preliminary study highlights the potential of tRFs as biomarkers or therapeutic targets for CD5+ R/R DLBCL.
More Related Videos
07:35Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
Published on: October 11, 2018
15:07VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
Published on: December 28, 2015